• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by CryoPort Inc.

    3/12/26 4:17:33 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001247309
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CRYOPORT, INC.
    SEC File Number
    001-34632
    Address of Issuer
    112 Westwood Place, Suite 350
    Brentwood
    TENNESSEE
    37027
    Phone
    (949) 470-2300
    Name of Person for Whose Account the Securities are To Be Sold
    ROBERT S. STEFANOVICH
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    38700300385.534985613503/12/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/12/2026Exercise of options under a registered planIssuerCheckbox not checked3870003/12/2026Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/12/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Robert Steven Stefanovich

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CYRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYRX

    DatePrice TargetRatingAnalyst
    8/6/2025Sector Weight → Overweight
    KeyBanc Capital Markets
    8/6/2025$16.00Market Perform → Outperform
    Leerink Partners
    7/22/2025$13.00Overweight
    Stephens
    3/24/2025$10.00Neutral → Buy
    UBS
    12/19/2024$11.00Buy
    Guggenheim
    12/19/2024$11.00Buy
    Canaccord Genuity
    8/7/2024$20.00 → $8.00Buy → Hold
    Jefferies
    7/31/2024$19.00 → $15.00Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $CYRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mandalam Ramkumar sold $115,540 worth of shares (11,570 units at $9.99), decreasing direct ownership by 13% to 80,758 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    12/12/25 5:30:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J exercised 50,000 shares at a strike of $2.66 and sold $242,738 worth of shares (25,000 units at $9.71), increasing direct ownership by 95% to 51,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    9/12/25 5:30:14 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hariri Robert J sold $43,000 worth of shares (5,000 units at $8.60), decreasing direct ownership by 16% to 26,275 units (SEC Form 4)

    4 - Cryoport, Inc. (0001124524) (Issuer)

    8/29/25 6:46:12 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

    Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designe

    2/11/26 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    SEC Filings

    View All

    SEC Form 144 filed by CryoPort Inc.

    144 - Cryoport, Inc. (0001124524) (Subject)

    3/12/26 4:17:33 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by CryoPort Inc.

    10-K - Cryoport, Inc. (0001124524) (Filer)

    3/5/26 4:53:43 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CryoPort Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cryoport, Inc. (0001124524) (Filer)

    3/3/26 5:10:46 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cryoport upgraded by KeyBanc Capital Markets

    KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight

    8/6/25 7:50:22 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00

    8/6/25 7:21:40 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens resumed coverage on Cryoport with a new price target

    Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00

    7/22/25 7:52:13 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Financials

    Live finance-specific insights

    View All

    Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

    FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th

    3/3/26 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

    NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd

    2/17/26 8:00:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Reports Third Quarter 2025 Financial Results

    Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in

    11/4/25 4:05:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CryoPort Inc.

    SC 13G - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 4:02:52 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/14/24 1:34:13 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CryoPort Inc.

    SC 13G/A - Cryoport, Inc. (0001124524) (Subject)

    11/13/24 7:16:51 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYRX
    Leadership Updates

    Live Leadership Updates

    View All

    Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

    Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i

    1/14/25 8:30:00 AM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cryoport Announces Appointment of Linda Baddour to its Board of Directors

    NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She

    3/3/21 4:08:00 PM ET
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Appoints Martin Schmieg to Board of Directors

    BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L

    12/1/20 6:30:00 AM ET
    $BCTX
    $CLBS
    $CYRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Managed Health Care